Medpace Holdings, Inc. (MEDP) on Decifer

Decifer ranks MEDP number 56 of 277 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 68% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 20% a year, profits grew 20% over the past year, and growth is speeding up, not slowing down.
• It keeps a healthy share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• It is riding an active market tailwind and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Returns near 68% with revenue growing about 20% make it one of the cleanest businesses on the list, but no worldview role and momentum of 14 out of 35 keep it from the top.

The current read

The evidence on MEDP lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Themes

• GLP-1 & Metabolic Health: Medpace sits in the cro / cdmo layer of the GLP-1 & Metabolic Health story.

Read the full MEDP research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.